<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00201851</url>
  </required_header>
  <id_info>
    <org_study_id>OSU-0483</org_study_id>
    <nct_id>NCT00201851</nct_id>
  </id_info>
  <brief_title>Adjuvant Oophorectomy and Tamoxifen in Premenopausal Women With Hormone Receptor-Positive Breast Cancer</brief_title>
  <official_title>Phase III Randomized Study of Immediate Versus Luteal Phase Adjuvant Oophorectomy and Tamoxifen in Premenopausal Women With Hormone Receptor-positive Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>International Breast Cancer Research Foundation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>International Breast Cancer Research Foundation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial tests surgical oophorectomy (removal of ovaries) plus Tamoxifen, done at different
      times in the menstrual cycle, as adjuvant therapy for invasive breast cancer in 510
      premenopausal women with Hormone Receptor-positive Breast Cancer. This study is recruiting at
      hospitals in Philippines, Vietnam, and Morocco.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2004</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease-free Survival</measure>
    <time_frame>two- to three-year accrual and initial two or more years of follow-up period</time_frame>
    <description>5-year disease-free survival</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">740</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Immediate surgery</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patient assigned to immediate surgical oophorectomy/mastectomy and Tamoxifen</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Scheduled surgery</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient scheduled for mid-luteal phase surgical oophorectomy/mastectomy plus Tamoxifen</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Immediate Surgery - nonrandomized</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patient in mid-luteal phase at time of enrollment. Assigned to immediate surgical oophorectomy/mastectomy plus Tamoxifen without randomization</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tamoxifen</intervention_name>
    <description>20 mg po daily x 5 years</description>
    <arm_group_label>Immediate surgery</arm_group_label>
    <arm_group_label>Scheduled surgery</arm_group_label>
    <arm_group_label>Immediate Surgery - nonrandomized</arm_group_label>
    <other_name>NolvadexÂ®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Surgery: Oophorectomy</intervention_name>
    <description>Group A-Surgical oophorectomy and mastectomy in estimated 5 days in mid-luteal phase of menstrual cycle (b, c) Group B-Surgical oophorectomy and mastectomy (1-6 days from randomization)(b, c) Group C-Surgical oophorectomy and mastectomy(1-6 days from registration)(c)</description>
    <arm_group_label>Immediate surgery</arm_group_label>
    <arm_group_label>Scheduled surgery</arm_group_label>
    <arm_group_label>Immediate Surgery - nonrandomized</arm_group_label>
    <other_name>ovary removal surgery</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Open for accrual in Asia only

          -  Female age 18-50,

          -  premenopausal with regular cycles (&gt;25-35 in length)

          -  fine-needle aspiration diagnosis

          -  Stage II-IIIA hormone receptor positive invasive breast cancer

          -  No prior radiation or chemotherapy

          -  Must be surgical candidate for bilateral oophorectomy
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard R. Love, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>International Breast Cancer Research Foundation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institute of Oncology</name>
      <address>
        <city>Rabat</city>
        <country>Morocco</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vicente Soto Memorial Medical Center</name>
      <address>
        <city>Cebu</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>East Avenue Medical Center</name>
      <address>
        <city>Manila</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Philippine General Hospital</name>
      <address>
        <city>Manila</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rizal</name>
      <address>
        <city>Manila</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santo Toma Hospital</name>
      <address>
        <city>Manila</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Danang General</name>
      <address>
        <city>Danang</city>
        <country>Vietnam</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital K, National Cancer Institute</name>
      <address>
        <city>Hanoi</city>
        <country>Vietnam</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hue Central</name>
      <address>
        <city>Hue</city>
        <country>Vietnam</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Morocco</country>
    <country>Philippines</country>
    <country>Vietnam</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2005</study_first_posted>
  <results_first_submitted>March 31, 2015</results_first_submitted>
  <results_first_submitted_qc>April 13, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 29, 2015</results_first_posted>
  <last_update_submitted>April 13, 2015</last_update_submitted>
  <last_update_submitted_qc>April 13, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 29, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Asian</keyword>
  <keyword>Premenopausal</keyword>
  <keyword>Women</keyword>
  <keyword>Oophorectomy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
    <mesh_term>Tamoxifen</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>A - Scheduled Surgery</title>
          <description>Patient scheduled for mid-luteal phase surgical oophorectomy/mastectomy plus Tamoxifen
Tamoxifen: 20 mg po daily x 5 years
Surgery: Oophorectomy: Group A-Surgical oophorectomy and mastectomy in estimated 5 days in mid-luteal phase of menstrual cycle (b, c) Group B-Surgical oophorectomy and mastectomy (1-6 days from randomization)(b, c) Group C-Surgical oophorectomy and mastectomy(1-6 days from registration)(c)</description>
        </group>
        <group group_id="P2">
          <title>B - Immediate Surgery</title>
          <description>Patient assigned to immediate surgical oophorectomy/mastectomy and Tamoxifen
Tamoxifen: 20 mg po daily x 5 years
Surgery: Oophorectomy: Group A-Surgical oophorectomy and mastectomy in estimated 5 days in mid-luteal phase of menstrual cycle (b, c) Group B-Surgical oophorectomy and mastectomy (1-6 days from randomization)(b, c) Group C-Surgical oophorectomy and mastectomy(1-6 days from registration)(c)</description>
        </group>
        <group group_id="P3">
          <title>C- Immediate Surgery - Nonrandomized</title>
          <description>Patient in mid-luteal phase at time of enrollment. Assigned to immediate surgical oophorectomy/mastectomy plus Tamoxifen without randomization
Tamoxifen: 20 mg po daily x 5 years
Surgery: Oophorectomy: Group A-Surgical oophorectomy and mastectomy in estimated 5 days in mid-luteal phase of menstrual cycle (b, c) Group B-Surgical oophorectomy and mastectomy (1-6 days from randomization)(b, c) Group C-Surgical oophorectomy and mastectomy(1-6 days from registration)(c)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="252"/>
                <participants group_id="P2" count="257"/>
                <participants group_id="P3" count="231"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="244"/>
                <participants group_id="P2" count="255"/>
                <participants group_id="P3" count="230"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Ineligible post enrollment</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Baseline measures were not available on all participants.</population>
      <group_list>
        <group group_id="B1">
          <title>A - Scheduled Surgery</title>
          <description>Patient scheduled for mid-luteal phase surgical oophorectomy/mastectomy plus Tamoxifen
Tamoxifen: 20 mg po daily x 5 years
Surgery: Oophorectomy: Group A-Surgical oophorectomy and mastectomy in estimated 5 days in mid-luteal phase of menstrual cycle (b, c) Group B-Surgical oophorectomy and mastectomy (1-6 days from randomization)(b, c) Group C-Surgical oophorectomy and mastectomy(1-6 days from registration)(c)</description>
        </group>
        <group group_id="B2">
          <title>B - Immediate Surgery</title>
          <description>Patient assigned to immediate surgical oophorectomy/mastectomy and Tamoxifen
Tamoxifen: 20 mg po daily x 5 years
Surgery: Oophorectomy: Group A-Surgical oophorectomy and mastectomy in estimated 5 days in mid-luteal phase of menstrual cycle (b, c) Group B-Surgical oophorectomy and mastectomy (1-6 days from randomization)(b, c) Group C-Surgical oophorectomy and mastectomy(1-6 days from registration)(c)</description>
        </group>
        <group group_id="B3">
          <title>C- Immediate Surgery - Nonrandomized</title>
          <description>Patient in mid-luteal phase at time of enrollment. Assigned to immediate surgical oophorectomy/mastectomy plus Tamoxifen without randomization
Tamoxifen: 20 mg po daily x 5 years
Surgery: Oophorectomy: Group A-Surgical oophorectomy and mastectomy in estimated 5 days in mid-luteal phase of menstrual cycle (b, c) Group B-Surgical oophorectomy and mastectomy (1-6 days from randomization)(b, c) Group C-Surgical oophorectomy and mastectomy(1-6 days from registration)(c)</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="244"/>
            <count group_id="B2" value="255"/>
            <count group_id="B3" value="230"/>
            <count group_id="B4" value="729"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42.2" spread="4.5"/>
                    <measurement group_id="B2" value="42.3" spread="4.7"/>
                    <measurement group_id="B3" value="42.1" spread="4.4"/>
                    <measurement group_id="B4" value="42.2" spread="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="244"/>
                    <measurement group_id="B2" value="255"/>
                    <measurement group_id="B3" value="230"/>
                    <measurement group_id="B4" value="729"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Estrogen receptor status</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="226"/>
                    <measurement group_id="B2" value="235"/>
                    <measurement group_id="B3" value="217"/>
                    <measurement group_id="B4" value="678"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Progesterone receptor status</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="218"/>
                    <measurement group_id="B2" value="234"/>
                    <measurement group_id="B3" value="219"/>
                    <measurement group_id="B4" value="671"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HER2/Neu status</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="32"/>
                    <measurement group_id="B4" value="118"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="146"/>
                    <measurement group_id="B2" value="160"/>
                    <measurement group_id="B3" value="153"/>
                    <measurement group_id="B4" value="459"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of positive axillary nodes</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="96"/>
                    <measurement group_id="B2" value="111"/>
                    <measurement group_id="B3" value="103"/>
                    <measurement group_id="B4" value="310"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1-3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                    <measurement group_id="B2" value="73"/>
                    <measurement group_id="B3" value="56"/>
                    <measurement group_id="B4" value="189"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="81"/>
                    <measurement group_id="B2" value="70"/>
                    <measurement group_id="B3" value="68"/>
                    <measurement group_id="B4" value="219"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Pathologic tumor size</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.5" spread="2.8"/>
                    <measurement group_id="B2" value="4.7" spread="3.2"/>
                    <measurement group_id="B3" value="4.1" spread="2.3"/>
                    <measurement group_id="B4" value="4.5" spread="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Progesterone level on day of surgery (ng/ml)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="75"/>
                    <measurement group_id="B2" value="158"/>
                    <measurement group_id="B3" value="74"/>
                    <measurement group_id="B4" value="307"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2-4.99</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="118"/>
                    <measurement group_id="B2" value="57"/>
                    <measurement group_id="B3" value="117"/>
                    <measurement group_id="B4" value="292"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Disease-free Survival</title>
        <description>5-year disease-free survival</description>
        <time_frame>two- to three-year accrual and initial two or more years of follow-up period</time_frame>
        <group_list>
          <group group_id="O1">
            <title>A - Scheduled Surgery</title>
            <description>Patient scheduled for mid-luteal phase surgical oophorectomy/mastectomy plus Tamoxifen
Tamoxifen: 20 mg po daily x 5 years
Surgery: Oophorectomy: Group A-Surgical oophorectomy and mastectomy in estimated 5 days in mid-luteal phase of menstrual cycle (b, c) Group B-Surgical oophorectomy and mastectomy (1-6 days from randomization)(b, c) Group C-Surgical oophorectomy and mastectomy(1-6 days from registration)(c)</description>
          </group>
          <group group_id="O2">
            <title>B - Immediate Surgery</title>
            <description>Patient assigned to immediate surgical oophorectomy/mastectomy and Tamoxifen
Tamoxifen: 20 mg po daily x 5 years
Surgery: Oophorectomy: Group A-Surgical oophorectomy and mastectomy in estimated 5 days in mid-luteal phase of menstrual cycle (b, c) Group B-Surgical oophorectomy and mastectomy (1-6 days from randomization)(b, c) Group C-Surgical oophorectomy and mastectomy(1-6 days from registration)(c)</description>
          </group>
          <group group_id="O3">
            <title>C- Immediate Surgery - Nonrandomized</title>
            <description>Patient in mid-luteal phase at time of enrollment. Assigned to immediate surgical oophorectomy/mastectomy plus Tamoxifen without randomization
Tamoxifen: 20 mg po daily x 5 years
Surgery: Oophorectomy: Group A-Surgical oophorectomy and mastectomy in estimated 5 days in mid-luteal phase of menstrual cycle (b, c) Group B-Surgical oophorectomy and mastectomy (1-6 days from randomization)(b, c) Group C-Surgical oophorectomy and mastectomy(1-6 days from registration)(c)</description>
          </group>
        </group_list>
        <measure>
          <title>Disease-free Survival</title>
          <description>5-year disease-free survival</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="244"/>
                <count group_id="O2" value="255"/>
                <count group_id="O3" value="230"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64"/>
                    <measurement group_id="O2" value="71"/>
                    <measurement group_id="O3" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Over entire course of study</time_frame>
      <group_list>
        <group group_id="E1">
          <title>A - Scheduled Surgery</title>
          <description>Patient scheduled for mid-luteal phase surgical oophorectomy/mastectomy plus Tamoxifen
Tamoxifen: 20 mg po daily x 5 years
Surgery: Oophorectomy: Group A-Surgical oophorectomy and mastectomy in estimated 5 days in mid-luteal phase of menstrual cycle (b, c) Group B-Surgical oophorectomy and mastectomy (1-6 days from randomization)(b, c) Group C-Surgical oophorectomy and mastectomy(1-6 days from registration)(c)</description>
        </group>
        <group group_id="E2">
          <title>B - Immediate Surgery</title>
          <description>Patient assigned to immediate surgical oophorectomy/mastectomy and Tamoxifen
Tamoxifen: 20 mg po daily x 5 years
Surgery: Oophorectomy: Group A-Surgical oophorectomy and mastectomy in estimated 5 days in mid-luteal phase of menstrual cycle (b, c) Group B-Surgical oophorectomy and mastectomy (1-6 days from randomization)(b, c) Group C-Surgical oophorectomy and mastectomy(1-6 days from registration)(c)</description>
        </group>
        <group group_id="E3">
          <title>C- Immediate Surgery - Nonrandomized</title>
          <description>Patient in mid-luteal phase at time of enrollment. Assigned to immediate surgical oophorectomy/mastectomy plus Tamoxifen without randomization
Tamoxifen: 20 mg po daily x 5 years
Surgery: Oophorectomy: Group A-Surgical oophorectomy and mastectomy in estimated 5 days in mid-luteal phase of menstrual cycle (b, c) Group B-Surgical oophorectomy and mastectomy (1-6 days from randomization)(b, c) Group C-Surgical oophorectomy and mastectomy(1-6 days from registration)(c)</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="230"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Pregnancy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Endocervical cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="230"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nosocomial pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="230"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Venous thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="230"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="230"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Richard R. Love</name_or_title>
      <organization>International Breast Cancer Research Foundation</organization>
      <phone>608-698-7881</phone>
      <email>richardibcrf@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

